IPS Academy College Of Pharmacy, Rajendra Nagar, A.B. Road, Indore - 452012 (M.P.).
Over the past five years, biochip technology has made huge strides that have changed molecular diagnostics, personalized medicine, and especially point-of-care (POC) testing. Because more and more people want quick, cheap, and accurate tests, new microarrays, lab-on-a-chip systems, and sensors based on nanotechnology are providing integrated solutions that bring lab-level analysis right to the patient. This review combines recent studies to look at how these technologies have affected diagnostic accuracy, time, and cost in healthcare settings. The accuracy of diagnostics has improved. Multi-cancer early detection (MCED) biochips have an average specificity of 96.6%, and single-cancer early detection (SCED) biochips have an average sensitivity of 86.4%. Biomimetic nanostructures make it possible to detect exosomes with very high sensitivity, and nanoelectronic biochips can analyze markers like nitric oxide in real time with detection limits as low as 12 nM. Automated "sample-to-answer" lab-on-a-chip systems and paper-based POC tests that give results in minutes have cut down on the time it takes to diagnose a problem by a huge amount. Also, costs have gone down a lot because platforms have been made smaller, which means less need for expensive infrastructure, and because cheap, eco-friendly materials like edible nano-conductive paste for printed sensors have been made.
Biochip technology has undergone significant advancements in the past five years, revolutionizing molecular diagnostics, point-of-care testing, and personalized medicine. These innovations have directly impacted diagnostic accuracy, reduced turnaround time, and lowered costs in healthcare applications [1–3]. This report synthesizes data from recent research to evaluate how these technological improvements have transformed healthcare diagnostics. Organ-on-chip (OOC) platforms—microfluidic cell culture systems that simulate physiology at the tissue and organ levels [9,10]—have advanced incredibly quickly. These platforms offer portable and affordable biomedical tools for disease modeling [12,13], pharmacological research [14,15], and personalized medicine [5,6], and they have the potential to significantly improve our understanding of tissue and organ physiology [11]. The term "chip" in OOC refers to the original fabrication methods [7,16] (such as a modified type of photolithography) that were employed in the production of computer microchips [17]. This enables us to regulate the sizes and forms of surface features on the nm to mscale [18].
The demand for rapid, accurate, and affordable diagnostics has intensified due to rising healthcare costs, the need for early disease detection, and the shift toward personalized medicine. Biochips—encompassing microarrays, lab-on-a-chip systems, nanotechnology-based sensors, and paper-based platforms—have emerged as disruptive innovations, offering integrated solutions for sample preparation, detection, and analysis [4]. This report examines the measurable impact of these advancements on diagnostic accuracy, time efficiency, and cost-effectiveness.
BioMEMS
Since the 1950s, advancements in microfabrication technology have progressed swiftly with the introduction of planar technologies in microelectronics [19,20]. In the early 1980s, advancements in microelectronic systems, coupled with the benefits of miniaturization and parallel manufacturing, led to the emergence of microelectromechanical systems (MEMS). This concept involves the integration of mechanical and electrical functions within a single chip featuring small structures for diverse applications, including biochemical and chemical engineering fields [2,19]. Microfabrication techniques employed in the semiconductor industry for the production of integrated circuits (IC) are similarly utilized in the fabrication of MEMS microdevices [1]. Typically, the fabrication of micro/nano scale structures on planar substrates is accomplished through the repetition of specific orders of photolithography, etching techniques, and thin-film deposition steps. Figure 1 illustrates the fundamental aspects of the photolithography process. The process begins with the application of photoresist at a specific rotational speed to achieve the desired thickness on the substrate. The subsequent step involves heating the photoresist to facilitate the evaporation of any solvents. The photoresist must be irradiated with UV light while being passed through a photomask. A post-exposure bake may be necessary to expedite the curing process of the photoresist. In positive tone interactions, areas exposed to UV radiation are eliminated following development.
BIOCHIP WORKING MECHANISM
Diagnostic tests are the initial step in protecting public health because they impact 70% of medical treatment options, regardless of whether the disease is contagious or not . It is very important to comprehend the mechanics underlying the operation of biochips as a disease detection tool. Based on the idea of particular interactions between biomolecules to achieve the detection of nucleic acids, proteins, etc., biochips are microchip technologies that process and analyze biological information. They primarily refer to the solid phase of biomolecules (oligonucleotides, complementary DNA, peptides, proteins, etc.) on a carrier, such as a solid chip surface, to form a miniature bioanalysis system. As a result, the biochip test results will provide a useful foundation for accurate and customized care. As part of the process, many particular infectious diseases and illnesses are spread from animals to people[2,3]. Zoonotic diseases are a serious health risk as well as a difficult scientific and policy problem where effective outcome control depends on social, cultural, and political norms and values [2]. Biochips are a technology that will enable early diagnosis and prevention of numerous diseases that pose a threat to human health by bringing about revolutionary advances in genetic, immunological, microbiological, and clinical chemistry diagnostics[4].
LAB-ON-CHIP
Devices based on Lab-on-a-Chip (LOC) technology combine several laboratory operations onto a single chip that is only a few square millimeters to a few square centimeters in size. When compared to traditional laboratory testing, these platforms offer smaller, automated, integrated, and parallelized chemical and/or biological analyses that can give bio-chemical assays at a very small scale that are more affordable, quicker, controlled, and perform better. Small fluid quantities, less than a few picoliters, can be handled by these microengineered devices. [3]. These miniature platforms have the capacity to evaluate a small number of microdroplets of whole blood, plasma, saliva, tears, urine, or perspiration for medical diagnostic purposes [6]. In many clinical studies and biological research, where typically relatively little amounts of patient samples are available, this last is crucial. On the other hand, automation that removes human-interfering characteristics might boost analytical confidence [5].
LAB-ON-A-CHIP DEVICES FOR POINT-OF-CARE DIAGNOSTICS
Point-of-care (POC) diagnostic systems are compact medical devices that offer the quickest and most convenient diagnostic findings [4]. Although medical experts can carry out these diagnostic procedures, patients can conduct the tests in a variety of locations, such as their homes, laboratories, hospitals, or clinics, and using these instruments does not require training. Interest in creating POC systems has increased due to the growing demand for home care testing, such as blood glucose monitoring in diabetic patients, and the quick diagnosis of severe illnesses, such as acute myocardial infarction. The time of analysis in LOC for POC testing is significantly reduced by the large surface area to volume ratio in microfluidic devices [8]. This offers the opportunity for prompt diagnosis and prompt treatment at the point of care. Furthermore, these POC devices make it simple for non-expert people to work and acquire test results. The main type of POC systems that use a membrane or paper strip to validate the presence or absence of a target analyte, such as host antibodies or pathogen-antigens, are lateral flow tests or capillary driven test strips, which have been widely used since the 1960s [7]. Capillary action is created by introducing a tiny amount of sample, and the sample travels along the channel and passes through the membrane containing the labels and immobilized antibodies. The sample will attach to the immobilized antibodies and labels and keep moving along the device if the targeted particles are present. The binding reagents on the membrane will adhere to the targeted drug at the test line as the sample travels. When a colored line appears, the test results can be read out qualitatively; alternatively, when the device is combined with reader technology, the results can be read out quantitatively [10].
DIAGNOSTIC IMPROVEMENTS
Recent biochip technologies have demonstrated substantial gains in sensitivity and specificity across a range of diagnostic applications:
REDUCTION IN DIAGNOSTIC TIME
Biochip innovations have streamlined sample processing and enabled rapid analysis:
COST REDUCTION
Advancements have led to more affordable diagnostic solutions:
Table 1: Comparative Performance Metrics of Recent Biochip Technologies
|
Biochip Application |
Sensitivity (%) |
Specificity (%) |
Detection Limit |
Time to Result |
Cost Impact |
Reference |
|
MCED Cancer Biochips |
69.2 |
96.6 |
N/A |
N/A |
Reduced |
[16] |
|
SCED Cancer Biochips |
86.4 |
80.0 |
N/A |
N/A |
Reduced |
[17] |
|
Exosome Diagnostic Biochip |
High* |
High* |
N/A |
Minutes |
Reduced |
[18] |
|
NO Nanozyme Biochip |
N/A |
N/A |
12 nM |
Real-time |
Reduced |
[19] |
|
Paper-Based POC Tests |
Improved |
Improved |
N/A |
Minutes |
Low-cost |
[20] |
|
Edible Nano-Conductive Paste |
N/A |
N/A |
N/A |
Rapid |
Very low-cost |
[21] |
*High = Demonstrated ultrasensitive and specific detection
†Improved = Recent advances have enhanced sensitivity and specificity
DIAGNOSTIC ACCURACY
The meta-analysis of commercial biochip products highlights a significant improvement in both sensitivity and specificity over previous technologies. MCED biochips approach near-perfect specificity (96.6%), minimizing false positives—a critical factor in cancer screening—while SCED biochips deliver higher sensitivity (86.4%), ensuring more cases are correctly identified (7). The integration of multiple data types (e.g., protein, DNA, RNA markers) further increases predictive accuracy by up to 9% compared to single-factor assays [22-26].
Exosome biochips utilizing quantum dots and photonic crystals achieve ultrasensitive detection of disease-specific markers such as Glypican-1 in pancreatic cancer exosomes, enabling noninvasive diagnostics with high specificity (8). Similarly, nanozyme-based biochips provide highly sensitive molecular analysis for physiological markers like nitric oxide, supporting both in vitro and in vivo applications [27-30].
TIME EFFICIENCY
Automated lab-on-a-chip platforms now integrate complex sample preparation steps—extraction, amplification, detection—into a single workflow, drastically reducing manual intervention and time-to-result [31]. Wireless multi-channel systems further enhance throughput by enabling parallel analysis of multiple samples or analytes [32].
Paper-based POC tests have evolved to deliver rapid results (often within minutes), with recent improvements addressing previous limitations in sensitivity and result ambiguity. Multiplexing capabilities allow simultaneous detection of multiple pathogens or biomarkers in a single assay [33-35].
COST REDUCTION
The shift toward eco-friendly materials (e.g., edible nano-conductive paste) enables the production of disposable sensors at minimal cost while reducing environmental impact (2). Miniaturized integrated biochips eliminate the need for costly laboratory equipment and specialized personnel, making advanced diagnostics accessible at the point of care or in resource-limited settings [36].
Disruptive innovations such as next-generation sequencing biochips consolidate multiple diagnostic tests into a single assay, lowering overall costs while expanding the scope of detectable conditions [37].
Table 2: Impact Summary—Diagnostic Accuracy, Time, And Cost
|
Advancement |
Diagnostic Accuracy Impact |
Time Reduction Impact |
Cost Reduction Impact |
Reference |
|
Automated Lab-on-a-Chip |
Improved sensitivity/specificity |
Significant (integrated) |
Lower labor/infrastructure |
[38] |
|
Nanozyme Sensor Biochips |
High sensitivity/low detection limit |
Real-time/multichannel |
Lower device cost |
[39] |
|
Exosome Nanostructure Chip |
Ultrasensitive/specific |
Rapid (minutes) |
Reduced reagent/sample use |
[40] |
|
Paper-Based POC Tests |
Enhanced via multiplexing/ML |
Minutes |
Very low-cost |
[41] |
|
Eco-Friendly Materials |
Maintains accuracy |
Rapid |
Minimal material cost |
[42] |
|
Next-Gen Sequencing Chips |
High accuracy/multifactorial |
Consolidated workflow |
Single test replaces many |
[43] |
FUTURE ASPECTS
While significant progress has been made, some gaps remain:
CONCLUSION
Advancements in biochip technology from 2019–2024 have led to demonstrable improvements in diagnostic accuracy (with sensitivity up to 86.4% for SCED chips and specificity up to 96.6% for MCED chips), significant reductions in time-to-result (from hours/days to minutes/real-time), and substantial cost savings through miniaturization, automation, eco-friendly materials, and consolidation of diagnostic workflows [45-49]Over the past five years, advancements in biochip technology—including automated lab-on-a-chip systems, nanostructure-based signal amplification, eco-friendly sensor materials, multiplexed paper-based POC tests, and next-generation sequencing platforms—have significantly increased diagnostic accuracy (with sensitivities up to 86.4% and specificities up to 96.6%), reduced diagnostic turnaround times to minutes or real-time analysis, and lowered costs through material innovation and workflow consolidation in healthcare applications[1,7,35,45,49].
REFERENCES
Nitin Singh Kushwaha, Dr. Dinesh Kumar Jain, Biochip Technology: Improving Diagnostic Accuracy, Speed, and Cost in Healthcare, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 5, 1732-1740, https://doi.org/10.5281/zenodo.20082660
10.5281/zenodo.20082660
